ORIGINAL ARTICLE

Therapeutic efficacy in a hemophilia B model using a biosynthetic mRNA liver depot system

F DeRosa, B Guild, S Karve, L Smith, K Love, JR Dorkin, KJ Kauffman, J Zhang, B Yahalom, DG Anderson, and MW Heartlein

DNA-based gene therapy has considerable therapeutic potential, but the challenges associated with delivery continue to limit progress. Messenger RNA (mRNA) has the potential to provide for transient production of therapeutic proteins, without the need for nuclear delivery and without the risk of insertional mutagenesis. Here we describe the sustained delivery of therapeutic proteins in vivo in both rodents and non-human primates via nanoparticle-formulated mRNA. Nanoparticles formulated with lipids and lipid-like materials were developed for delivery of two separate mRNA transcripts encoding either human erythropoietin (hEPO) or factor IX (hFIX) protein. Dose-dependent protein production was observed for each mRNA construct. Upon delivery of hEPO mRNA in mice, serum EPO protein levels reached several orders of magnitude (>125,000-fold) over normal physiological values. Further, an increase in hematocrit (Hct) was established, demonstrating that the exogenous mRNA-derived protein maintained normal activity. The capacity of producing EPO in non-human primates via delivery of formulated mRNA was also demonstrated as elevated EPO protein levels were observed over a 72-h time course. Exemplifying the possible broad utility of mRNA drugs, therapeutically relevant amounts of human FIX (hFIX) protein were achieved upon a single intravenous dose of hFIX mRNA-loaded lipid nanoparticles in mice. In addition, therapeutic value was established within a hemophilia B (FIX knockout (KO)) mouse model by demonstrating a marked reduction in Hct loss following injury (incision) to FIX KO mice.

INTRODUCTION

The application of nucleic acids for therapeutic use has been of interest to the scientific community for decades. While viral systems have shown great promise and recent success, challenges associated with safety, manufacturing and potency continue to persist. Non-viral systems have many potential advantages but have proven challenging to translate. In general, this work has predominantly focused on the use of plasmid DNA (gene therapy), small interfering RNA (RNA interference), antisense oligonucleotides, microRNA (translation repression) and aptamers. Messenger RNA (mRNA) has garnered much less attention during this time, perhaps due to the widespread consideration of its transient nature, and only recently has been publicized to have therapeutic value in the treatment of various diseases.

Systemic mRNA therapy (MRT) is a new approach to the delivery of therapeutic proteins in vivo, using biosynthetic mRNA transcripts as the source for therapeutic protein. Protein production derived from such exogenous mRNA takes advantage of the endogenous protein translational machinery within the body along with all of the endogenous post-translational modifications and processing machinery that are present in human cells and tissues. Theoretically, this approach could enable the treatment of many diseases, including those in which protein-based therapeutics are unattainable, such as large, transmembrane proteins; heavily processed, post-translationally modified proteins; or proteins requiring cytoplasmic delivery. In addition to this, MRT could provide flexibility with respect to delivery within the body. The specific site of delivery and subsequent translation need not be within the target organ for therapeutic treatment. Protein production derived from the delivered mRNA can remain intracellular or can be secreted to treat the respective disease systemically. Finally, MRT has potential advantages over other nucleic acid protein replacement platforms such as gene therapy, including the lack of requirement for nuclear localization and elimination of insertional mutagenesis risks.

As with almost all nucleic acid-based therapeutics, intracellular delivery is required to achieve function. Over the years, many different modalities have been examined, including viral vectors, polymers, lipid nanoparticles (LNPs), and covalent conjugation. Here we develop therapeutic LNPs, using lipid and lipid-like materials for the delivery of mRNA to hepatocytes. mRNA is notoriously labile, especially under biological environments such as exposure to endo- and exonucleases present within plasma. Encapsulation of RNA within LNPs can provide for sustained RNA stability. In general, LNPs are formulated with either a cationic or ionic lipid or lipidoid.
several helper lipids and a nucleic acid payload, which can facilitate accumulation in specific sites within the body by manipulation of size and/or inclusion of targeting agents.\textsuperscript{49–55} While considerable progress has been made in the clinical development of small interfering RNA delivery systems, the intravenous delivery of LNP-encapsulated mRNA in primates has not been demonstrated.\textsuperscript{56–64}

Here we describe the first example of efficacy in a human disease mouse model using a lipidoid-based LNP formulation for systemic delivery of mRNA, \textit{in vivo}. A formulation containing the cationic lipidoid C12-200 was developed for the delivery of \textit{in vitro}-synthesized mRNA. LNPs containing mRNA constructs for either human erythropoietin (hEPO) or human factor IX (hFIX) were developed. Delivery of the mRNA to hepatocytes was confirmed using \textit{in situ} hybridization (ISH) methods. Robust protein production from both exogenously synthesized mRNA transcripts was observed and quantified in multiple species, including non-human primates. Further, pharmacodynamic effects were assessed and proof of efficacy was established within a hemophilia B (FIX knockout (KO)) disease model.\textsuperscript{65}

\textbf{RESULTS}
We examined the potential of LNP-formulated mRNA for two therapeutic proteins, hEPO and hFIX, as well as the utility of FIX in a relevant disease model. Quantitative measurement demonstrated that the desired proteins derived from exogenous human mRNAs were delivered at supraphysiological levels via LNP formulations. Protein secretion resulted in potent pharmacodynamic effects as well as therapeutic efficacy in a KO mouse model.

\textit{In vivo} hEPO protein production
To evaluate the ability of mRNA-encapsulated lipidoid nanoparticles to facilitate the delivery of mRNA, we monitored both hEPO mRNA as well as hEPO protein levels in the serum over a 1-week time period. This was performed as a single-dose administration (1.0 mg kg\textsuperscript{-1} based on encapsulated mRNA) given intravenously. All formulations were well tolerated in the mice at the given dose with no observable adverse events.

ISH methods were used to evaluate the delivery of hEPO mRNA to the liver. As represented in Figure 1, a strong positive signal for hEPO mRNA was detected from the earliest time point within the experiment (30 min post administration). hEPO mRNA was detected in both the sinusoidal cells as well as hepatocytes within treated mouse livers with no cross-reactivity observed for endogenous mouse EPO transcripts (Figure 1). mRNA was still present at detectable levels within the hepatocytes up to 72 h after a single dose.

As expected for a secreted protein, hEPO was detected in the serum at various time points after administration of hEPO mRNA-loaded C12-200 lipidoid nanoparticles (Figure 2). hEPO protein

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{example-figure}
\caption{Detection of exogenous hEPO mRNA via ISH. Positive staining was observed in hepatocytes as well as sinusoidal cells. Strong detection was observed out to 72 h with remnant staining 1 week post administration.}
\end{figure}
Delivery of therapeutic proteins via mRNA
F DeRosa et al

(701)

was present at markedly higher quantities than physiological levels in a normal, healthy mouse at almost every time point examined, yielding a maximum serum concentration at ~6 h post administration. As shown in Figure 2 and listed in Table 1, upon treatment with a 1.0-μg kg−1 dose of EPO mRNA-encapsulated LNP5, ~11 μg of hEPO protein per ml of serum can be produced. This is several orders of magnitude (>125 000-fold) over the normal human physiological level of EPO (average normal levels reported to be 31.5–150 pg ml−1, average ~90 pg ml−1).66 Measurable levels of protein (~47 ng ml−1, Table 1) were still observed at 72 h with an appreciable increase over normal physiological levels. This indicates that after 3 days, levels ~520-fold over baseline physiological quantities were maintained. Further, 1 week after a single dose of exogenous hEPO mRNA, hEPO protein was present at slightly above normal physiological levels (~120 pg ml−1 serum). These data demonstrate the ability of organs, which internalize LNP-delivered mRNA to act as a ‘depot’ for the production (and secretion) of hEPO protein.

This experiment also revealed the rapid onset of protein production derived from such delivery. Approximately 190 ng ml−1 of hEPO protein can be observed within 30 min of dosing C12-200-based lipidoid nanoparticles delivering hEPO mRNA. Therefore, an ~2000-fold increase over normal physiological levels could be achieved in less than 1 h. Further, by 3 h, levels of hEPO protein reached >112 000-fold over normal.

To verify that the protein produced via mRNA-loaded lipidoid nanoparticles was active, we measured hematocrit (Hct) changes due to expression of the protein. Hct changes were reported to be 31.5–150 pg ml−1, average ~90 pg ml−1).66 This is several orders of magnitude (>125 000-fold) over the normal human physiological level of EPO (average normal levels reported to be 31.5–150 pg ml−1, average ~90 pg ml−1).66 Measurable levels of protein (~47 ng ml−1, Table 1) were still observed at 72 h with an appreciable increase over normal physiological levels. This indicates that after 3 days, levels ~520-fold over baseline physiological quantities were maintained. Further, 1 week after a single dose of exogenous hEPO mRNA, hEPO protein was present at slightly above normal physiological levels (~120 pg ml−1 serum). These data demonstrate the ability of organs, which internalize LNP-delivered mRNA to act as a ‘depot’ for the production (and secretion) of hEPO protein.

This experiment also revealed the rapid onset of protein production derived from such delivery. Approximately 190 ng ml−1 of hEPO protein can be observed within 30 min of dosing C12-200-based lipidoid nanoparticles delivering hEPO mRNA. Therefore, an ~2000-fold increase over normal physiological levels could be achieved in less than 1 h. Further, by 3 h, levels of hEPO protein reached >112 000-fold over normal.

To verify that the protein produced via mRNA-loaded lipidoid nanoparticles was active, we measured hematocrit (Hct) levels in mice following delivery of EPO mRNA. Hct changes were monitored for hEPO protein production via serum analysis over time (Figure 3). Each monkey received a single bolus, intravenous injection via the ear vein of either hEPO mRNA LNPs (two monkeys) or control LNP encapsulating nonsense mutated, untranslatable mRNA (one monkey). The control formulation was dosed at 0.025 mg kg−1 while the two treated monkeys were dosed at 0.025 and 0.050 mg kg−1. All formulations were well tolerated by the monkeys with no clinical signs and normal physiological liver enzyme levels (alanine transaminase/aspartate transaminase) observed (Supplementary Table 1).

While accounting for dose differences, the pharmacokinetic profile of EPO production in the cynomolgus monkeys shows striking similarity to what was observed in mice (Figure 2; Table 1). Serum EPO levels reach their maximum 6 h post administration, while still detectable after 72 h at as low a dose of 0.025 mg kg−1. Monkeys treated with a dose of 0.050 mg kg−1 demonstrated hEPO protein levels of ~9000 pg ml−1 (6 h time point), which results in an increase over physiological levels by over 100-fold.

Table 1. Concentrations of secreted human EPO protein over time as measured via ELISA analysis (as depicted in Figure 1)

| Time post administration (h) | Secreted human EPO protein (ng ml−1) |
|-----------------------------|-------------------------------------|
| 0.50                        | 188                                 |
| 3                           | 10 125                              |
| 6                           | 11 296                              |
| 12                          | 85 21                               |
| 24                          | 61 14                               |
| 48                          | 34 1                                |
| 72                          | 47 0                                |
| 1 week                      | 0.12                                |

Abbreviations: ELISA, enzyme-linked immunosorbent assay; EPO, erythropoietin. EPO mRNA (1.0 mg kg−1) was delivered via C12-200-based lipidoid nanoparticles. Values are depicted as ng of human EPO protein per ml of serum.

Table 2. Hct levels of each group over a 15-day observation period

| Formulation | Dose (μg per animal) | Hct levels, mean (%) ± s.e.m. |
|-------------|----------------------|-------------------------------|
|             |                      | Day – 4                      | Day 7                       | Day 10                      | Day 15                      |
| C12-200     | 30                   | 50.8 ± 1.8                   | 58.3 ± 3.3                  | 62.8 ± 1.3                  | 59.9 ± 3.3                  |
| C12-200     | 10 (x3)              | 52.2 ± 0.5                   | 55.3 ± 2.3                  | 63.3 ± 1.6                  | 62.3 ± 1.9                  |

Abbreviation: Hct, hematocrit. Mice were either dosed as a single, 30-μg intravenous injection, or three 10-μg intravenous injections, every other day.

Figure 2. Quantification of secreted hEPO protein levels as measured via enzyme-linked immunosorbent assay (N=4 mice per group, error bars represent s.d.). The protein detected is a result of its production from EPO mRNA delivered intravenously via a single dose of LNP5 (1.0 mg kg−1) encapsulated hEPO mRNA over time (1 week). Aliquots of mouse serum were collected at the designated time points.

Figure 3. Hct levels in mice (N=4, error bars represent s.e.m.) treated with either single intravenous dose of hEPO mRNA-loaded LNP5 (200 ng/ml) or three injections (d1, d3 and d5). Whole-blood samples were taken before injection (day – 4), day 7, day 10 and day 15.
In sum, these data clearly demonstrate the ability to effectively deliver mRNA to the liver when administering mRNA-loaded LNPs. The exogenous mRNA was efficiently processed by the host translational machinery to produce a fully formed, functional protein. Further, this depot effect provides large quantities of desired protein secreted systemically resulting in extended pharmacokinetic plasma exposure profiles and substantial pharmacodynamic effects within these mice.

**In vivo hFIX protein production**

To examine the potential of mRNA nanoparticles for the treatment of hemophilia B, we formulated hFIX mRNA-loaded LNPs and evaluated their activity in vivo. Successful delivery of hFIX mRNA upon intravenous injection of a single 1.0 mg kg$^{-1}$ dose was determined by ISH (Supplementary Figure 1). Staining patterns of hFIX mRNA within both sinusoidal cells and hepatocytes were equivalent to what was observed with EPO formulations (Figure 1). Again, no cross-reactivity was observed for endogenous mouse FIX transcripts within the liver. The strongest signal occurs at the earliest time point analyzed (30 min) and diminishes over the course of 3 days, with detectable mRNA still present at 72 h post administration.

A pharmacokinetic analysis over 72 h showed that MRT-derived FIX protein could be detected at all time points tested (Figure 5). The peak plasma concentration was observed at 12 h post injection with a value of ~ 4.4 μg of FIX protein per ml of plasma. This robust protein production followed by secretion into the blood stream for a sustained blood residence time represents another successful example of the depot effect upon application of LNP-mediated MRT.

To further establish the potential for MRT as a viable therapeutic modality, we applied our hFIX mRNA-loaded LNPs in a hemophilia B mouse model. Upon treatment of the mice with hFIX mRNA, we observed a marked increase in activity resulting in 40.9% and 87% of wild-type levels for the 0.25 and 0.50 mg kg$^{-1}$ groups, respectively.

Furthermore, given the high FIX levels observed, we expected such doses to be therapeutic. We therefore hypothesized that upon application of an incision wound, prolonged bleeding would occur in the untreated KO mice as opposed to hFIX mRNA-treated cohorts. These effects could be measured via changes in Hct levels (that is, lower levels were a result of extended blood loss). To achieve this, at ~12 h post administration, the mice were subjected to a small surgical incision on the back of the animal. This time point was selected to represent the maximum observed hFIX protein plasma levels from the pharmacokinetic data previously obtained in wild-type mice. As represented in Figure 8, pre-treatment Hct levels averaged at ~47.7%. Final Hct readings were taken from blood samples obtained 12 h post incision (24 h post administration). Saline-treated FIX KO mice had a final Hct level of 17.9% representing a 62.5% overall decrease from pre-treatment levels. Mice that were treated with hFIX mRNA had much more sustained Hct levels measured at 36.1% and 100% activity of FIX protein. The FIX KO saline-treated group showed trace amounts of FIX activity (~1.15%) of wild-type levels. This is consistent with, although slightly lower than, the 8% residual activity reported previously as measured via an alternate method. Upon treatment of the mice with hFIX mRNA, we observed a marked increase in activity resulting in 40.9% and 87% of wild-type levels for the 0.25 and 0.50 mg kg$^{-1}$ groups, respectively.

**Figure 5.** Quantification of secreted hFIX protein levels measured using enzyme-linked immunosorbent assay (N=4 mice per group, error bars represent s.d.). FIX protein is produced from FIX mRNA delivered via nanoparticles (1.0 mg kg$^{-1}$ hFIX mRNA per single intravenous dose, based on encapsulated mRNA). FIX protein is monitored in plasma through 72 h.

**Figure 6.** Quantification of secreted hFIX protein levels in FIX KO mice (N=5, error bars represent s.d.) after single, intravenous dose (0.25 and 0.50 mg kg$^{-1}$, based on encapsulated mRNA). FIX protein is measured in plasma 12 and 24 h post administration. Saline represents control group.
Delivery of therapeutic proteins via mRNA
F DeRosa et al

Figure 7. FIX protein activity as measured by a chromogenic assay. Controls include saline-treated wild-type (C57BL/6) and FIX KO cohorts. All values are normalized to wild-type FIX activity values.

Figure 8. Hct levels of blood from FIX KO mice (N=5, error bars represent s.d.) 12 h post incision (24 h post injection). Mice were either dosed with 0.25 or 0.50 mg kg−1 of C12-200-based hFIX mRNA-loaded LNPS. Control FIX KO mice were treated with saline.

39.0% for 0.25 and 0.50 mg kg−1 dosing, respectively. The overall drop in Hct for the treated groups was significantly inhibited (24.3% and 18.2% overall decrease for 0.25 and 0.50 mg kg−1, respectively) as compared with the saline treatment, which can be attributed to the presence of active FIX protein to restore clotting and prevent further bleeding.

DISCUSSION
Here we describe the successful application of two separate mRNA-loaded lipidoid nanoparticle systems toward hepatocyte deposition of exogenous mRNA and subsequent high-level protein production sustained over several days, creating a depot system. Such a system is presumed to be the result of uptake and clearance mechanisms with independent kinetic constants. These include the kinetics of cellular uptake of the LNPs, the kinetics of intracellular compartment escape (endosomal/lysosomal), the kinetics of release of the exogenous mRNA, the half-life of the mRNA, as well as the rate of translation of the mRNA into protein. Further, with respect to secreted proteins, such processes may occur in multiple organs to which the LNP was distributed, resulting in contribution toward the total circulating pool of protein produced from the exogenous mRNA. Previous studies using this system (not reported) have demonstrated that >80% of the packaged mRNA is deposited in the liver. Moreover, an additional complicating factor concerns possible differences in the accessibility and function of the endogenous translational machinery that could vary with different organs and is beyond the scope of this work.

Observations of hepatocellular mRNA delivery and protein production were consistent between the two mRNA constructs. The first mRNA transcript delivered using this approach was designed to produce hEPO protein. EPO is a hormone, which has long been used as a therapeutic with applications in anemia and designed to produce hEPO protein. EPO is a hormone, which has fi

production were consistent between the two mRNA constructs.

The potential of this formulation was further demonstrated by the application of LNP-encapsulated hePO mRNA in non-human primates. A pharmacokinetic profile of serum hePO protein levels was obtained in male cynomolgus monkeys when administered at two separate doses (0.025 and 0.050 mg kg−1, Figure 4) that was remarkably similar to the results seen in mice. Serum levels of EPO within both dose regimens could be detected up to 72 h post administration within maximum levels reached by 6 h (matching trends observed in mice vide supra). Control formulations consisting of an untranslatable (nonsense mutated, non-protein producing) mRNA construct resulted in no EPO protein detection and prevent further bleeding.

High levels of protein production were observed following a single treatment of hEPO MRT in wild-type mice as quantified and depicted in Figure 2. Mouse serum levels reached >125 000-fold normal physiological levels of EPO protein (>11.2 μg EPO per ml of serum) within the first 6 h of administration. As noted above, rapid onset of protein production can be observed within 30 min of administration while levels reached several orders of magnitude above normal levels by 3 h post dose. Such observations indicate the potential use of MRT as a protein production ‘depot’ therapy. In the example presented here, a single 1.0 mg kg−1 produces a sustained exposure of hEPO protein that is detectable for 1 week post administration.

Hct levels were monitored before and post treatment with EPO MRT. Two dosing regimens were applied to wild-type mice consisting of either a single, 30 μg bolus intravenous injection or three 10 μg hEPO mRNA-loaded C12-200-based LNPS dosed every other day (days 1, 3 and 5). Both dosing regimens resulted in an ~20% change in Hct as represented in Figure 3. These findings confirm that hormonal activity is maintained within the secreted, MRT-derived hEPO protein upon encapsulation and delivery of the respective mRNA via LNPs.

Patients suffering from this disease have an inability to form proper blood clotting, resulting in varying degrees of bleeding episodes as well as other complications. The only currently approved treatment modality for this disease is the direct infusion of FIX enzyme, either from recombinant or plasma-derived sources. Patients suffering
from hemophilia B have been classified based on the percentage of functional FIX protein within the body: >5–40% of normal physiological levels is defined as mild; 1–5% of normal physiological levels is defined as moderate; <1% of normal physiological levels is defined as severe. The relative ratio of each classification level within the patient population has not been fully determined, however it has been reported that up to ~70% of patients suffer from moderate to severe forms of the disease.

hFIX mRNA was encapsulated in an identical fashion to that described above using hEPO mRNA C12-200-based LNPs. Encapsulation efficiency as well as particle size was consistent with the hEPO mRNA formulations. A pharmacokinetic study to assess FIX protein production (and subsequent secretion) was performed similarly to the EPO MRT study described above. Wild-type mice were treated with a 1.0-mg kg~−1~ single, intravenous dose of C12-200-based hFIX mRNA-loaded LNPs, and were analyzed at selected time points. To confirm specific delivery and enrichment of hepatic cells, ISH methods were used. Similar staining patterns and amounts were observed when delivering hFIX mRNA via LNPs as the previous EPO study (vide supra, Supplementary Figure 1). Upon quantitative assessment of plasma hFIX protein levels within the treated mice, we observed sustained protein production, with subsequent secretion, for 72 h after a single, intravenous administration. Again, high-level protein production resulted in maximum plasma levels reaching ~4.40 μg of hFIX protein per ml within 12 h of dosing (Figure 5). While normal physiological levels of FIX protein are relatively high (2–3 μg ml~−1~ plasma), the observed FIX protein production in wild-type mice via FIX MRT can be considered to be well within therapeutic levels. More specifically, moderate to severe patients represent only up to 5% active protein available yet constitute up to ~70% of the patient population. This equates to ~100 ng FIX protein per ml plasma maximum. On the basis of a single 1.0-mg kg~−1~ dose of hFIX mRNA-loaded LNPs, we achieve ~40-fold higher than this level. Therefore, a significant portion of the patient population may be candidates for a possible future treatment with this modality.

To establish the possible therapeutic value of FIX MRT, we applied this LNP technology toward a hemophilia B mouse model. This model entails a FIX transgenic KO, which has been reported to have minimal residual FIX activity. Traditional measures of efficacy in hemophilia models involve comparisons of bleeding times or volumes upon tail snip. However, such methods are sensitive to many variables, and protocols vary considerably within the literature. We sought to establish an alternative measure for efficacy that would provide a surrogate for FIX protein function. To this end, we measured Hct levels pre and post incision to serve as a reflection of the degree of bleeding, which occurred within treated and untreated animals. Mice deficient in FIX protein would demonstrate prolonged bleeding episodes upon injury, which could be directly compared with those mice, which have been pre-treated with FIX MRT.

FIX KO mice were treated with a single dose of FIX mRNA-loaded C12-200 nanoparticles at either 0.25 or 0.50 mg kg~−1~. Plasma levels of hFIX protein were measured at 12 and 24 h post administration (Figure 6). Plasma levels of FIX protein at 12 h reached ~1.8 μg ml~−1~ plasma and 400 ng ml~−1~ plasma for 0.50 and 0.25 mg kg~−1~ doses, respectively. These FIX concentrations correspond to 90% (0.50 mg kg~−1~) and 20% (0.25 mg kg~−1~) of normal physiological levels and are well within therapeutic range. This is reflected both in the activity data and the Hct observations. Detectable levels were still observed 24 h post administration at 724 ~250 ng ml~−1~ for the respective doses. Protein levels observed in treated wild-type mice were equivalent for identical doses (Supplementary Figure 2).

Further, FIX activity measurements were conducted on all treated and untreated mice. Figure 7 represents a comparison of activity of treated mice as compared with normal FIX activity levels in untreated, wild-type mice (normalized to 100%). A single 0.50-mg kg~−1~ dose of FIX MRT resulted in a restoration of activity to 87% of wild-type levels. This level far surpasses the range of ‘mild’ defined as 5–40% activity. Moreover, a single dose of only 0.25 mg kg~−1~ provided activity of ~40% of wild-type levels. These increases in activity levels are statistically significant when compared with the saline group, although one mouse demonstrated abnormally high activity (105% of wild-type levels) in the lower-dose cohort (0.25 mg kg~−1~).

At 12 h post administration, a group of mice were subjected to a small incision (~1 cm) in the thoracic region of each mouse followed by suturing while a separate group was killed. After 12 more hours (24 h total post administration), the injured mice were killed and Hct levels were measured and compared with pre-treatment baseline values. As depicted in Figure 8, a substantial decrease in Hct was observed in saline-treated KO mice as compared with pre-treatment levels (17.9% (saline) vs 47.7% (pre-treatment)). This decrease in Hct was inhibited upon treatment with FIX MRT as a function of dose (36.1% and 39.0% for 0.25 and 0.50 mg kg~−1~, respectively). Wild-type mice were treated in an identical fashion with respect to both dose and incision with no change in Hct levels observed. Such production of active FIX protein after a single dose of FIX MRT demonstrates therapeutic potential relevant for enabling treatment of severe through mild classifications of hemophilia B patient population.

Summary
In summary, we have established successful encapsulation and delivery of mRNA constructs to the liver using C12-200-based LNP technology. Hepatocyte deposition and detection of active mRNA was observed for two separate transcripts, hEPO and hFIX mRNA. Furthermore, high level protein production (μg ml~−1~) and secretion sustained for up to 1 week post injection was achieved. Active MRT-derived protein was confirmed through pharmacodynamic measures (increase in Hct (EPO)) and therapeutic means (prevention of blood loss) in a hemophilia B (FIX KO) disease model. These examples demonstrate the applicability of formulated mRNA to treat not only organs of direct LNP uptake but also sites within the body, which benefit from the prolonged exposure of MRT-derived protein secreted into the bloodstream.

MATERIALS AND METHODS
Lipid materials
The formulations described herein consisted of a multi-component lipid mixture of specific ratios using a combination of lipidoid, helper lipids and PEGylated lipids designed to encapsulate mRNA therapeutic molecules. C12-200 was synthesized as previously described. DOPE (1,2-dioleoyl-sn-glycerol-3-phosphoethanolamine, Avanti Polar Lipids, Alabaster, AL, USA) and cholesterol (Sigma, St Louis, MO, USA) served as helper lipids within the nanoparticle. The PEGylated lipid selected was a dimyrstoyl glycerol–polyethylene glycol (PEG) analog with a PEG molecular weight of ~2000 Da (DMG-PEG-2K) purchased from NOF (White Plains, NY, USA).

mRNA material
hEPO and hFIX were synthesized by in vitro transcription via T7 RNA polymerase from a plasmid DNA template encoding the gene using unmodified nucleotides, which was followed by the addition of a 5′-cap structure (Cap 1) and a 3′-poly(A) tail of ~250 nucleotides in length as determined by gel electrophoresis. Fixed S′ and 3′-untranslated regions were constructed to flank the coding sequences of each mRNA. The control mRNA consisted of a nonsense mutated coding sequence designed to prevent protein production.

Formulation protocol
Example 1. Aliquots of 50 mg ml~−1~ ethanolic solutions of C12-200, DOPE, cholestrol and DMG-PEG2K were mixed and diluted with ethanol to 3 ml final volume. Separately, an aqueous buffered solution (10 mm
citrate/150 mM NaCl, pH 4.5) of hEPO mRNA was prepared from a
1-mg ml⁻¹ stock. The lipid solution was injected rapidly into the aqueous
mRNA solution and shaken to yield a final suspension in 20% ethanol. The
resulting nanoparticle suspension was filtered, diafiltrated with 1×
phosphate-buffered saline (pH 7.4), concentrated and stored at
2–8 °C. Final concentration = 0.20 mg ml⁻¹ EPO mRNA (encapsulated).
% Encapsulation = 75%; % recovery = 81%; Zave = 91 nm (DV(50) = 75 nm);
polydispersity = 0.14.

Example 2. Aliquots of 50 mg mL⁻¹ ethanolic solutions of C12-200, DOPE,
cholersterol and DMG-PEG2K were mixed and diluted with ethanol to 3 ml
final volume. Separately, an aqueous buffered solution (10 mM citrate/ 150 mM NaCl, pH 4.5) of hFIX mRNA was prepared from a 1-mg ml⁻¹ stock.
The lipid solution was injected rapidly into the aqueous mRNA solution
and shaken to yield a final suspension in 20% ethanol. The resulting
nanoparticle suspension was filtered, diafiltrated with 1× phosphate-
buffered saline (pH 7.4), concentrated and stored at 2–8 °C. Final concentration = 0.20 mg ml⁻¹ FIX mRNA (encapsulated). % Encapsulation
= 78%; % recovery = 79%; Zave = 86 nm (DV(50) = 69 nm); polydispersity = 0.16.

In vivo animal models
EPO and FIX pharmacokinetic studies used 6- to 8-week-old male mice
(CD-1). For FIX efficacy experiments, 10- to 12-week-old male mice (C57BL/ 6J) were used as wild-type reference controls. Male FIX KO mice
(8–18 weeks old) were used for a single intravenous injection as a total dose volume of 1 ml via ear vein injection. Select FIX KO mice were subjected to incision to determine efficacious
treatment. At 12 h post dose administration, animals were anesthetized with isoflurane before surgery. With the animals in a prone position, the incision site (previously shaved) was aseptically treated using betadine
followed by alcohol. The animals were subjected to a small (~1.0 cm)
skin incision on the dorsal thoracic region and the incision was closed with surgical sutures.

Analysis of protein produced via intravenously delivered mRNA-
loaded nanoparticles
Injection protocol. All pharmacokinetic studies were performed using
male CD-1 mice of ~6-8 weeks of age at the beginning of each
experiment. Samples were introduced by a single bolus tail vein injection
of the specified dose of encapsulated EPO or FIX mRNA-loaded LNPs. Mice
were killed and perfused with saline at the designated time points.

Isolation of organ tissues for analysis. The liver of each mouse was
collected and stored in either 10% neutral buffered formalin or snap-frozen
and stored at ~80 °C for analysis.

Isolation of plasma/serum for analysis. All animals were killed by CO₂
asphyxiation at respective time points post administration (±5%) followed
by thoracotomy and terminal cardiac blood collection. Whole blood
(maximal obtainable volume) was collected via cardiac puncture on killed
animals. For serum collection, whole blood was placed into serum
separator tubes, allowed to clot at room temperature for at least 30 min,
centrifuged at 22 ± 5 °C at 9300 g for 10 min and extracted. For plasma
collection, whole blood was placed into either lithium heparin tubes or
citrate-coated tubes and processed to plasma. For interim blood
collections, ~40–50 μl of whole blood were collected via facial vein
puncture or tail snap. Samples collected from non-treatment animals were
used as a baseline level for comparison to study animals.

Enzyme-linked immunosorbent assay analysis. Quantification of EPO
protein was performed following procedures reported for hEPO enzyme-
linked immunosorbent assay analysis kit (Quantikine IVD, R&D Systems,
Catalog # DEP-00; Minneapolis, MN, USA). Positive controls used consisted of
ultrapure and tissue culture grade recombinant hEPO protein (R&D
Systems, Catalog # 286-EP and 287-TC, respectively). Blood samples were
taken at designated time points and processed as described above. Detection
was monitored via absorption (450 nm) on a Molecular Devices
Flex Station instrument (Sunnyvale, CA, USA). Quantification of FIX protein
was performed following procedures reported for hFIX ELISA kit (AssayMax, Assay Pro, Catalog # EF1009-1; St Charles, MO, USA). High

Delivery of therapeutic proteins via mRNA
F De Rosa et al

specificity for the human forms of each respective protein was obtained
with no cross-reactivity observed in mouse samples (EPO/FIX) and minimal
cross-reactivity observed in monkey serum samples (EPO).

Hct analysis
Whole-blood samples were collected in heparinized micro-capillary blood
collection tubes and centrifuged at 10 000–15 000 g for 5 min at ambient
temperature. Packed cell volume was calculated vs total volume to obtain
Hct values.

FIX activity assay
FIX activity measurements in plasma samples were performed using the
Rossik Factor IX Activity Chromogenic Assay (ROX Factor IX 900020,
Mölndal, Sweden) according to the manufacturer’s instructions. Samples
were collected 12 h post dose administration.

hEPO and hFIX ISH assay
The detection of exogenous hEPO mRNA and hFIX mRNA was performed
by Advanced Cell Diagnostics (ACD, Hayward, CA, USA) using proprietary
technology involving a probe design strategy that allows simultaneous
signal amplification and background suppression to achieve single-
molecule visualization while preserving tissue morphology. Tissues and
cells mounted on slides are first pre-treated (antigen retrieval) to prepare
for hybridization. Oligonucleotide target probes (up to 20 probe pairs) are
hybridized to the RNA in the sample, followed by a series of steps and
washes designed to amplify the signal. The probe sets were designed to
not cross-react with mouse, rat, pig and rhesus monkey.

CONFLICT OF INTEREST
FD, BG and MWH are inventors on patent applications filed in 2009 and 2011
covering delivery of mRNA and those such as EPO and Factor IX (Shire
Pharmaceuticals). The remaining authors declare no conflict of interest.

ACKNOWLEDGEMENTS
We thank Kari Harbert for her work on breeding the factor IX knockout mouse colony,
and Kelly Daly for dose administration on all mouse studies. We also acknowledge
Lisa Louth and Cindy Bell for activity assay experiments. FIX KO mouse colony
was obtained at Jackson Laboratories via licensing through the University of North
Carolina, Chapel Hill.

REFERENCES
1 Alvarez-Salas LM. Nucleic acids as therapeutic agents. Curr Top Med Chem
2008; 8: 1379–1404.
2 Vannucci L, Lai M, Chiupess F, Ceccherini-Neri L, Pistello M. Viral vectors: a
look back and ahead on gene transfer technology. New Microbiol 2013; 36:
1–22.
3 Yin H, Kanasty RL, Eltoukhy AA, Vegas AJ, Dorkin JR, Anderson DG. Non-viral
vectors for gene-based therapy. Nat Rev 2014; 15: 541–555.
4 O’Reilly M, Kohn DB, Bartlett J, Benson J, Brooks PJ, Byrne BJ et al. Gene therapy
to treat genetic diseases: from animal research to clinical translation. Nat
Rev Genet 2013; 14: 355–362.
5 Cotrim AP, Baum BJ. Gene therapy: some history, applications, problems and
prospects. Toxicol Pathol 2008; 36: 97–103.
6 Wirth T, Parker N, Yla-Hertuala S. History of gene therapy. Gene 2013; 525:
162–169.
7 Davidson BL, McCray PB Jr. Current prospects for rna interference-based ther-
apies. Nat Rev 2011; 12: 329–340.
8 Aagaard L, Rossi JJ. RNAi therapeutics: principles, prospects and challenges.
Adv Drug Deliv Rev 2007; 59: 75–86.
9 Dorsett Y, Tuschi T. siRNAs: applications in functional genomics and potential
as therapeutics. Nat Rev Drug Discov 2004; 3: 318–329.
10 Agrawal N, Dasaradhi PVN, Mohmmed A, Malhotra P, Bhatnagar RJ, Mukherjee
SK. RNA interference: biology, mechanism, and applications. Micrbiol Mol Biol
Rev 2005; 67: 657–685.
11 Aboul-Fadl T. Antisense oligonucleotides: the state of the art. Curr Med Chem
2005; 12: 2193–2214.
12 Dias N, Stein CA. Antisense oligonucleotides: basic concepts and mechanisms.
Mol Cancer Ther 2002; 1: 347–355.
Delivery of therapeutic proteins via mRNA
F DeRosa et al
